b'AML - NPM1 MRD AssayClinical InformationMinimal residual disease (MRD) detection in patients withLabPMMs NPM1 MRD test is a NGS-based, targeted, leukemia is useful for the clinical management of disease,deep-sequencing assay that can be used to and can facilitate the development of new therapies.detect NPM1 mutations that were previously identified in a primary sample. The sensitive assay reliably detects Mutations in the nucleophosmin (NPM1) gene representsequences present at 5 x 10 -5 .some of the most prevalent gene mutations in AML. 1NPM1 mutations predominantly occur in AML with normalMRD detection by Next-Generation Sequencing has cytogenetics and are of prognostic value, especially withindemonstrated utility in predicting clinical outcomes the context of FLT3 ITD mutations. Furthermore, becauseand in generating clinically actionable results, allowing NPM1 displays a homogeneous mutation pattern, this geneearly intervention, confirmation of disease status prior to represents an attractive target for MRD monitoring. 2 transplant, and increased confidence in remission status. References1.Falini B. et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med352:254266.2.Krnke J. et al. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from theGerman-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709-2716.38'